Candel Therapeutics, Inc. (CADL) company profile
Close on Nov 18, 2026Market cap $407.08MP/E –Yield –
About Candel Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies designed to stimulate systemic immune responses against cancer. Its investigational pipeline features two primary clinical candidates: aglatimagene besadenovec, an adenovirus-based therapy evaluated for localized prostate cancer, non-small cell lung cancer, and pancreatic cancer, and linoserpaturev, a herpes simplex virus construct being evaluated for recurrent high-grade glioma. The company also engineers early-stage solid tumor candidates using its enLIGHTEN discovery platform. Its target patients include individuals with solid tumors, especially those showing limited responses to standard oncology treatments.
Operationally, the company conducts multi-center clinical studies in the United States and Mexico. It retains development and commercialization rights across major territories, including the United States, Europe, and Asia, while utilizing third-party contract manufacturers for production. The business is incorporated in Delaware; its specific headquarters location is not stated in the text.
Summary of the business section of Candel Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Candel Therapeutics, Inc.
- Founded
- 2003
- Headquarters
- Needham, MA
- Address
- 117 Kendrick Street, Suite 450 02494
- Phone
- (617) 916-5445
- Website
- candeltx.com
- Employees
- 55, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- CADL
- Exchange
- Nasdaq
- IPO date
- Jul 28, 2021
- Shares outstanding
- 77M, Aug 6, 2026
- Public float
- $245.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1841387
- CUSIP
- 137404109
- ISIN
- US1374041093
- FIGI
- BBG00N0D4Z71
- Share class FIGI
- BBG00N0D4Z80
- EIN
- 52-2214851
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul Peter Tak | Chief Executive Officer, Director | 113,321 |
| Maria Ostrovsky | General Counsel | – |
| Seshu Tyagarajan | Chief Technology Officer | 76,865 |
| Mark E. Sims | Chief Commercial Officer | – |
| Francesca Barone | Chief Scientific Officer | 77,362 |
| Charles Schoch | Chief Financial Officer | 43,391 |
| William Garrett Nichols | Chief Medical Officer | 52,493 |
| Paul B. Manning | Director | 5,748,279 |
| Nicoletta Loggia | Director | 2,141 |
| Joseph C. Papa | Director | 102,271 |
| Martine Zimmermann | Director | – |
| Renee Gaeta | Director | – |
| Christopher Martell | Director | 698,863 |
| Maha Radhakrishnan | Director | – |
| Gary J. Nabel | Director | 5,353 |
| Diem Nguyen | Director | 10,000 |
| Edward J. Benz JR | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Paul Peter Tak, M.D., Ph.D., FMedSci Chief Executive Officer | $743.59K | $3.92M | $396.65K | $288.29K | $5.34M | +269% |
| Francesca Barone, M.D., Ph.D. Chief Scientific Officer | $483.31K | $857.80K | $206.43K | $14.00K | $1.56M | +115% |
| Charles Schoch Chief Financial Officer | $398.50K | $826.47K | $232.32K | $13.53K | $1.47M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 28, 2021
- Offer price
- $8.00
- Securities offered
- 9,000,000
- Gross proceeds
- $72.00M
- Exchange
- Nasdaq
- First trading day
- Jul 27, 2021
- First-day close
- $7.00-12.5%
- Lock-up ends (est.)
- Jan 23, 2022
“The initial public offering price is $8.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 55 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 21, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 28, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 19, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?